Genomic Surveillance Reveals Emergence and Spread of Macrolide-Resistant Mycoplasma pneumoniae in Australia During the 2023-2024 Epidemic - PubMed
4 hours ago
- #Macrolide Resistance
- #Genomic Surveillance
- #Mycoplasma pneumoniae
- Genomic surveillance in Australia during 2023-2024 revealed the emergence and spread of macrolide-resistant Mycoplasma pneumoniae (MRMP).
- MRMP was identified in 13% of genomes, with resistant strains previously reported only in Asia (ST3 and ST14).
- The study utilized a novel capture-based targeted metagenomic sequencing (tNGS) approach on 356 PCR-positive MP specimens.
- 124 high-quality genomes were recovered, showing a diverse population with P1 Type 1 (69%) and Type 2 (31%).
- MRMP cases were geographically widespread, suggesting importation and local transmission.
- Macrolide-susceptible clades (ST3, ST7, ST17, ST20) predominated (87%) and were associated with lower healthcare utilization compared to MRMP cases.
- The study highlights the need for ongoing MRMP surveillance to guide treatment and antimicrobial stewardship.
- Macrolides remain effective in Australia, but emerging MRMP strains require close monitoring.